SG11201408651TA - Use of markers in the diagnosis and treatment of prostate cancer - Google Patents

Use of markers in the diagnosis and treatment of prostate cancer

Info

Publication number
SG11201408651TA
SG11201408651TA SG11201408651TA SG11201408651TA SG11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA
Authority
SG
Singapore
Prior art keywords
keratin
international
iii
llll
prostate cancer
Prior art date
Application number
SG11201408651TA
Other languages
English (en)
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201408651TA publication Critical patent/SG11201408651TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201408651TA 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer SG11201408651TA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US201261718080P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
US201261718081P 2012-10-24 2012-10-24
PCT/US2013/048373 WO2014004931A1 (fr) 2012-06-27 2013-06-27 Utilisation de marqueurs dans le diagnostic et le traitement du cancer de la prostate

Publications (1)

Publication Number Publication Date
SG11201408651TA true SG11201408651TA (en) 2015-01-29

Family

ID=49783880

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408651TA SG11201408651TA (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Country Status (16)

Country Link
US (3) US20140038838A1 (fr)
EP (1) EP2867375B1 (fr)
JP (2) JP6352909B2 (fr)
KR (1) KR20150023904A (fr)
CN (1) CN104583422A (fr)
AU (1) AU2013284448B2 (fr)
BR (1) BR112014032728A2 (fr)
CA (1) CA2877721A1 (fr)
EA (1) EA201492284A1 (fr)
ES (1) ES2720763T3 (fr)
HK (1) HK1209792A1 (fr)
IL (1) IL236482A0 (fr)
MX (1) MX360236B (fr)
NZ (1) NZ703411A (fr)
SG (1) SG11201408651TA (fr)
WO (1) WO2014004931A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938809C (fr) * 2014-02-05 2023-03-14 Fujirebio Diagnostics Ab Composition et procede pour detecter une maladie neoplasique maligne
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
WO2016094425A1 (fr) * 2014-12-08 2016-06-16 Berg Llc Utilisation de marqueurs comprenant de la filamine a dans le diagnostic et le traitement du cancer de la prostate
CN107406510B (zh) 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
KR20190034503A (ko) * 2016-06-03 2019-04-02 이투빅스 코포레이션 전립선암-연관 항원을 사용한 종양 백신접종을 위한 조성물 및 방법
CA3030219A1 (fr) * 2016-07-07 2018-01-11 Berg Llc Marqueurs lipidiques, proteiques et metaboliques pour le diagnostic et le traitement du cancer de la prostate
WO2018189292A1 (fr) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarqueurs de cellules prostatiques résistantes à la castration
KR102405789B1 (ko) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물
CN109608536B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
CN109608537B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
CN114134223B (zh) * 2021-12-02 2022-10-11 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (de) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4208422A1 (de) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren
US6329179B1 (en) 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
US6207380B1 (en) 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU1449500A (en) 1998-10-22 2000-05-08 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
DE60140865D1 (de) 2000-03-27 2010-02-04 Univ Jefferson Zusammensetzungen und methoden zur identifizierung von krebszellen
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
ATE429511T1 (de) 2001-03-01 2009-05-15 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
EP2261368A1 (fr) 2002-03-13 2010-12-15 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
ATE516365T1 (de) 2002-05-21 2011-07-15 Sysmex Corp Nukleinsäureamplifikationsprimer zum nachweis von cytokeratinen und untersuchungsverfahren mit verwendung der primer
EP1585482A4 (fr) 2002-09-25 2009-09-09 Genentech Inc Nouvelles compositions et methodes de traitement du psoriasis
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (de) 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
EP2474631B1 (fr) 2002-12-20 2014-02-12 Celera Corporation Polymorphismes génétiques associés à l'infarctus du myocarde, procédés de détection et utilisations associées
WO2004076614A2 (fr) * 2003-02-27 2004-09-10 Bernd Hinzmann Sequences d'acide nucleique humaines issues de carcinomes de la prostate
WO2004085621A2 (fr) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Expression genetique dans le cancer du sein
WO2004111603A2 (fr) 2003-05-28 2004-12-23 Genomic Health, Inc. Marqueurs de l'expression genetique permettant de predire la reponse une chimiotherapie
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005007830A2 (fr) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate
CA2533803A1 (fr) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarqueurs de modulation des kinases dependantes des cyclines
EP1892306A3 (fr) 2003-10-06 2008-06-11 Bayer HealthCare AG Méthode et trousses pour évaluer un cancer
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
CN1743849A (zh) 2004-09-03 2006-03-08 上海透景生命科技有限公司 一种多肿瘤标志物并行检测的方法及试剂盒
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
WO2006048291A2 (fr) 2004-11-03 2006-05-11 Almac Diagnostics Limited Technologie de micro-reseaux de transcriptome et procedes d'utilisation de celle-ci
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US9234897B2 (en) 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
WO2006124836A1 (fr) 2005-05-13 2006-11-23 Duke University Signatures d'expression genetique pour la deregulation de mecanismes oncogeniques
WO2006127860A2 (fr) 2005-05-25 2006-11-30 Expression Pathology, Inc. Procede multiplex permettant une augmentation de la couverture proteomique a partir d'echantillons biologiques traites histopathologiquement a l'aide de preparations tissulaires liquides
WO2006127861A2 (fr) * 2005-05-25 2006-11-30 Expression Pathology, Inc. Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612021A1 (fr) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions et procedes de traitement et de diagnostic de cancer
EP1734118A1 (fr) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification de gènes modulateurs de la voie de signalisation JAK/STAT par criblage du génome à l'aide d'ARNi
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
WO2007119111A2 (fr) 2005-11-10 2007-10-25 Aurelium Biopharma Inc. Diagnostics tissulaires pour cancer de l'ovaire
EP1963860A1 (fr) 2005-12-19 2008-09-03 University of Hull Essai de criblage du cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (ja) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
WO2008013989A2 (fr) 2006-07-27 2008-01-31 Cell Genesys, Inc. Procédés et compositions pour identifier une réponse immunitaire cellulaire contre le cancer de la prostate
CA2660286A1 (fr) 2006-08-09 2008-02-21 Homestead Clinical Corporation Proteines specifiques d'organes et procedes d'utilisation
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
US8524493B2 (en) 2006-09-07 2013-09-03 Centre Hospitalier Universitaire De Montpellier Released cytokeratins as markers for epithelial cells
WO2008079269A2 (fr) 2006-12-19 2008-07-03 Genego, Inc. Nouveaux procédés pour une analyse fonctionnelle de données expérimentales à haut débit et groupes de gènes identifiés à partir de ceux-ci
CA2679664C (fr) * 2007-03-02 2017-04-25 Cell Genesys, Inc. Procedes et compositions pour identifier un cancer de la prostate ou une reponse immune humorale contre un cancer de la prostate
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (fr) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Procédés et compositions pour identifier le cancer de la prostate ou une réponse immunitaire à médiation humorale contre le cancer de la prostate
EP2559771A3 (fr) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Bio-marqueurs et méthodes pour déterminer la sensibilité aux modulateurs du recepteur du facteur de croissance de l'insuline (IGF1R).
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
US8889361B2 (en) 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
ATE524740T1 (de) 2007-12-10 2011-09-15 Hoffmann La Roche Seprase als krebsmarker
WO2009100029A1 (fr) 2008-02-01 2009-08-13 The General Hospital Corporation Utilisation de microvésicules dans le diagnostic, le pronostic et le traitement de maladies et d’affections médicales
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
EP2318543A2 (fr) 2008-07-16 2011-05-11 Dana-Farber Cancer Institute Inc. Signatures et déterminants de la pc associés au cancer de la prostate et leurs procédés d utilisation
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (fr) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
CN102209899B (zh) 2008-11-12 2014-05-07 霍夫曼-拉罗奇有限公司 作为癌症的标记物的pacap
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
CN102317784B (zh) 2008-12-22 2014-07-16 霍夫曼-拉罗奇有限公司 作为癌症标记物的armet
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012100536A (ja) 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
WO2010099918A1 (fr) 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Composition pharmaceutique et procédé d'identification d'une maladie cancéreuse et/ou inflammatoire chez un patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
WO2011040532A1 (fr) * 2009-10-02 2011-04-07 学校法人 久留米大学 Méthode de prédiction de l'effet thérapeutique d'une immunothérapie chez un patient atteint de cancer et/ou du pronostic après l'immunothérapie, et batterie de gènes et kit à utiliser pour sa mise en oeuvre
WO2011053837A1 (fr) 2009-10-29 2011-05-05 King Kutter, Inc. Dessoucheuse
EP2335838B1 (fr) 2009-12-18 2012-09-26 Deutsche Post AG Système et procédé de tri utilisant un dispositif portable
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
CA2795776A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarqueurs circulants pour une maladie
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (fr) * 2010-05-27 2011-11-30 Atlas Antibodies AB Biomarqueurs du cancer de la prostate
WO2012006634A2 (fr) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Thérapie peptidique par antigène prostatique spécifique (psa)
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
WO2012021969A1 (fr) * 2010-08-16 2012-02-23 Mount Sinai Hospital Marqueurs du tractus urogénital mâle
US20140148350A1 (en) * 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
WO2012031008A2 (fr) 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
US9255142B2 (en) 2010-09-09 2016-02-09 Beijing Cotimes Biotech Co., Ltd. Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
SG191028A1 (en) 2010-12-06 2013-07-31 Thd Spa Method for the diagnosis of a carcinoma and uses thereof
JP2014501388A (ja) 2010-12-24 2014-01-20 マップ ダイアグノースティックス ピーティーワイ エルティーディー 選択反応モニタリング（ｓｒｍ）による癌および他の病理学的実体のタンパク質プロファイル
EP2668503B1 (fr) 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Biomarqueurs combinatoires destinés aux applications cliniques mises en uvre pour la gestion des patients souffrants de cancer du poumon
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
KR101320633B1 (ko) 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
WO2012135397A2 (fr) 2011-03-29 2012-10-04 Lisanti Michael P Signatures géniques induites par le lactate et des cétones et leur utilisation pour le diagnostic d'une maladie et la prédiction d'un devenir clinique
WO2012174256A2 (fr) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Profils de méthylation de l'adn dans le cancer
ES2571380T3 (es) 2011-07-26 2016-05-25 Univ Salamanca Método para la detección de infiltración cancerosa en el sistema nervioso central
AU2012294458A1 (en) 2011-08-08 2014-02-27 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
EP2756298A4 (fr) 2011-09-12 2015-08-12 Creatics Llc Procédés non invasifs de détection de molécules cibles
WO2013134786A2 (fr) 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Compositions de biomarqueurs et procédés associés
WO2013148316A1 (fr) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarqueurs utilisables dans des applications de traitement par l'intégrine
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (zh) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
EP2895864B1 (fr) 2012-09-17 2021-03-10 AIT Austrian Institute of Technology GmbH Mathode et moyen de diagnostic du cancer du côlon
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
CA2902841A1 (fr) 2013-03-13 2014-10-02 Creatics Llc Procedes et compositions pour detecter un cancer du pancreas
SE538211C2 (sv) 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
WO2015042465A1 (fr) 2013-09-20 2015-03-26 Astute Medical, Inc. Méthodes et compositions pour le diagnostic et le pronostic d'appendicite et la différenciation des causes de la douleur abdominale

Also Published As

Publication number Publication date
CA2877721A1 (fr) 2014-01-03
EA201492284A1 (ru) 2015-11-30
WO2014004931A1 (fr) 2014-01-03
AU2013284448B2 (en) 2019-04-18
US20140038838A1 (en) 2014-02-06
ES2720763T3 (es) 2019-07-24
EP2867375A1 (fr) 2015-05-06
JP6581247B2 (ja) 2019-09-25
BR112014032728A2 (pt) 2017-11-28
EP2867375B1 (fr) 2019-02-27
KR20150023904A (ko) 2015-03-05
MX2015000008A (es) 2015-04-10
AU2013284448A1 (en) 2015-01-22
IL236482A0 (en) 2015-02-26
US20180031563A1 (en) 2018-02-01
US9797905B2 (en) 2017-10-24
JP2018163164A (ja) 2018-10-18
NZ703411A (en) 2017-09-29
EP2867375A4 (fr) 2016-06-01
HK1209792A1 (en) 2016-04-08
CN104583422A (zh) 2015-04-29
JP6352909B2 (ja) 2018-07-04
MX360236B (es) 2018-10-26
JP2015523569A (ja) 2015-08-13
US20160178632A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
SG11201408651TA (en) Use of markers in the diagnosis and treatment of prostate cancer
SG11201407569PA (en) Interrogatory cell-based assays for identifying drug-induced toxicity markers
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407370QA (en) Humanized il-7 rodents
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201408261UA (en) Syringe
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201406943XA (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201407890VA (en) Tetrahydropyrazolopyrimidine compounds
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201808812RA (en) Novel aav8 mutant capsids and compositions containing same
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201810287RA (en) Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
SG11201407880QA (en) Treatment of solid tumors using coenzyme q10